The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Case receives NCI merit extension

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

The Case Comprehensive Cancer Center earned an additional $12 million from NCI as a two-year merit-based extension. The center was the first of two NCI-designated comprehensive cancer centers to be awarded this distinction, followed by Lurie Cancer Center.

The center’s Cancer Center Support Grant was last renewed in 2017, when it received an “exceptional” rating along with $27.9 million to support research from 2018-2023. 

Since its founding in 1987 by Case Western Reserve and University Hospitals, the center has held an NCI designation; it attained “comprehensive” status in 1998. Cleveland Clinic formally joined the consortium in 2003.

Table of Contents

YOU MAY BE INTERESTED IN

Guest Editorial

Rathmell: We must support our junior colleagues
“Empathy and listening is a key place to start”

Just consider for a minute if this was the first year of running your lab, if you were on the job market as a physician or scientist right now, if you were a resident contemplating a career in cancer research after fellowship, if you were a graduate student or postdoc, if you were an undergraduate or a technician who was looking toward graduate school.
By W. Kimryn Rathmell
Guest Editorial

Weill Cancer Hub East to investigate connections between metabolism and anti-tumor immunity
Weill Cornell, Rockefeller, Princeton and the Ludwig Institute for Cancer Research showcase the power of collaboration

The immune system can be a powerful tool to control cancer. Immune cells within our body detect cancer cells and release payloads that kill them. Transformative science in the last decade has led to the development of therapies that enhance the ability of our immune cells to carry out this function. These therapies, including checkpoint blockade and CAR-T cells, have been lifesaving for many patients that before had untreatable cancer. But, sadly, a majority of patients with advanced solid tumors still succumb to their disease. 
By Jedd D. Wolchok, Joshua D. Rabinowitz and Sohail Tavazoie
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account